Search results
5-year relative survival rates for nasal cavity and paranasal sinus cancers. These numbers are based on people diagnosed with cancers of the nasal cavity or paranasal sinus between 2012 and 2018.
9 lut 2024 · For people diagnosed with nasal cavity or paranasal sinus cancer in the UK and Ireland: more than 70 out of 100 people (more than 70%) will survive their cancer for 1 year or more after diagnosis; around 50 out of 100 people (around 50%) will survive their cancer for 5 years or more after they are diagnosed
27 cze 2024 · Patients with adenocarcinoma and esthesioneuroblastoma had ideal overall survival prognosis, SCC (squamous cell carcinoma), SNMM (sinonasal mucosal melanoma), salivary carcinomas, SNUC (sinonasal undifferentiated carcinomas) poor, and SNEC (sinonasal neuroendocrine carcinoma) and NUT carcinoma (nuclear protein testis carcinoma) the worst prognosis.
6 cze 2022 · The five-year survival rate for localized nasal cavity and paranasal sinus cancer is about 86 percent. Regional — The cancer has spread from the sinus area to nearby lymph nodes or structures. The five-year survival rate for regional nasal cavity and paranasal sinus cancer is about 52 percent.
2 sie 2022 · The prognosis for patients with NUT carcinoma is poor, with a median survival time from diagnosis estimated at 6–7 months. 233 In one retrospective review of 48 cases, the estimated median PFS was 6.6 months (range, 4.7–8.4 months), and the median OS was 9.7 months (range, 6.6–15.6 months). 212 Another review of 54 patients reported a ...
If you have nasal cavity or paranasal sinus cancer, you may have questions about your prognosis. A prognosis is the doctor's best estimate of how cancer will affect someone and how it will respond to treatment. Prognosis and survival depend on many factors.
On multivariate analysis, increasing age, male sex, increasing T stage, increasing N stage, and increasing tumor grade each significantly reduced survival for nasal cavity cancer. Also, radiotherapy was associated with a significant reduction in overall survival.
